argenx announces results of Annual General Meeting of Shareholders

Rhea-AI Summary

May 10, 2022 - argenx SE (Euronext & Nasdaq: ARGX) announced that all resolutions at its Annual General Meeting of Shareholders were passed. Approved resolutions include the endorsement of the annual report for 2021, advisory vote on the remuneration report, and the re-appointment of several directors for varying terms. The Board was authorized to issue shares representing up to 10% of the outstanding capital for the next 18 months. Deloitte Accountants B.V. was appointed as the auditor for the 2022 financial year.

Positive

• All proposed resolutions at the Annual General Meeting were passed, ensuring business continuity.
• The annual report for the financial year 2021 was approved, reflecting the company's financial transparency.
• Key directors were re-appointed, providing stability in leadership.

Negative

• The authorization to issue shares up to 10% of outstanding capital could dilute existing shareholder value.

May 10, 2022

Breda, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that all proposed resolutions at its Annual General Meeting of Shareholders, held today at 10:00 a.m. CEST, were duly passed.

As part of the approved resolutions:

• The company's annual report and annual accounts for the financial year ending December 31, 2021, were approved;
• The advisory vote on the company's remuneration report for the financial year ending December 31, 2021, was passed;
• Tim Van Hauwermeiren has been re-appointed as executive director to the Board of Directors for a term of four (4) years;
• Peter Verhaeghe has been re-appointed as non-executive director to the Board of Directors for a term of two (2) years;
• Jim Daly has been re-appointed as non-executive director to the Board of Directors for a term of four (4) years;
• Werner Lanthaler has been re-appointed as non-executive director to the Board of Directors for a term of two (2) years;
• The Board of Directors was authorized to issue shares and grant rights to subscribe for shares in the share capital of the company for up to 10% of the outstanding share capital at the date of the meeting and for a period of 18 months from the meeting;
• The proposed amendments to the articles of association have been approved; and
• Deloitte Accountants B.V. has been appointed as the Company's auditor for the 2022 financial year.
  
  

The results of the votes and all documents relating to the shareholders’ meeting will be available on the Company’s website at www.argenx.com/investors/shareholder-meetings.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S. and Japan. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Twitter, and Instagram. 

For further information, please contact:

Media:
Kelsey Kirk
kkirk@argenx.com

Investors:
Beth DelGiacco
bdelgiacco@argenx.com

Michelle Greenblatt
mgreenblatt@argenx.com

FAQ

What resolutions were passed at argenx's Annual General Meeting on May 10, 2022?

All proposed resolutions, including the approval of the 2021 annual report and director re-appointments, were passed.

Who were re-appointed to the Board of Directors at argenx's AGM?

Tim Van Hauwermeiren, Jim Daly, and Werner Lanthaler were re-appointed as directors for varying terms.

What is the significance of the share issuance authorization approved by argenx's shareholders?

The Board was authorized to issue shares representing up to 10% of outstanding capital, potentially impacting shareholder ownership.

Who was appointed as the auditor for argenx in 2022?

Deloitte Accountants B.V. was appointed as the Company's auditor for the 2022 financial year.

When was the Annual General Meeting for argenx held?

The Annual General Meeting took place on May 10, 2022, at 10:00 a.m. CEST.